AviadoBio
Develops gene therapies for neurodegenerative diseases, with its lead candidate AVB-101 in a Phase 1/2 trial for genetic frontotemporal dementia.
aviadobio.com ↗Why it's here
Regained full rights to AVB-101 in March 2026 after Astellas let its option lapse, gained backing from the Treat FTD Fund, and opened a fourth Phase 1/2 dose cohort.
source: business-news-today.com- Focus
- Gene therapy
- Founded
- 2019
- Latest round
- Strategic equity, $20M from Astellas, Oct 2024
- Team size
- 51-200 people
- Registered office
- 20 Water Street, London, Tower Hamlets E14 5GXsource: find-and-update.company-information.service.gov.uk
- London presence
- HQsource: dealroom.co
- Investors
- Astellas, Treat FTD Fundsource: business-news-today.com
- Area
- Canary Wharf
- Nearest station
- Canary Wharf, 310 m
- Visas
- Licensed visa sponsor, listed as Aviadobio Limitedsource: gov.uk
- Elsewhere
- LinkedIn ↗
Verified 8 Oct 2026. How we verify · Suggest a fix
For AviadoBio
Work here? Show you're on the map. Add the badge to your site or README, or share the listing.
<a href="https://londonmempool.co.uk/c/aviadobio"><img src="https://londonmempool.co.uk/badge/aviadobio.svg" alt="AviadoBio is listed on London Mempool" width="357" height="28"></a>
Add ?theme=light to the image URL for light backgrounds.